B. Metzler seel. Sohn & Co. AG Buys 45 Shares of Chemed Co. (NYSE:CHE)

B. Metzler seel. Sohn & Co. AG boosted its stake in shares of Chemed Co. (NYSE:CHE) by 8.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 560 shares of the company’s stock after acquiring an additional 45 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in Chemed were worth $297,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in shares of Chemed in the fourth quarter worth $42,023,000. HighTower Advisors LLC raised its position in shares of Chemed by 78.0% in the 3rd quarter. HighTower Advisors LLC now owns 3,730 shares of the company’s stock valued at $2,246,000 after buying an additional 1,634 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of Chemed by 111.5% during the 3rd quarter. XTX Topco Ltd now owns 2,843 shares of the company’s stock worth $1,709,000 after acquiring an additional 1,499 shares during the period. Geode Capital Management LLC boosted its position in shares of Chemed by 4.9% during the 3rd quarter. Geode Capital Management LLC now owns 335,443 shares of the company’s stock worth $201,820,000 after acquiring an additional 15,791 shares in the last quarter. Finally, Signal Advisors Wealth LLC increased its stake in Chemed by 60.7% in the fourth quarter. Signal Advisors Wealth LLC now owns 4,995 shares of the company’s stock valued at $2,647,000 after acquiring an additional 1,886 shares during the last quarter. 95.85% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. StockNews.com raised Chemed from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Royal Bank of Canada lifted their target price on Chemed from $633.00 to $667.00 and gave the company an “outperform” rating in a research report on Friday, March 14th.

Chemed Price Performance

Shares of NYSE:CHE opened at $598.17 on Friday. The firm has a 50 day simple moving average of $580.24 and a 200 day simple moving average of $568.11. The company has a market cap of $8.76 billion, a price-to-earnings ratio of 30.23, a PEG ratio of 2.15 and a beta of 0.43. Chemed Co. has a one year low of $512.12 and a one year high of $632.53.

Chemed Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Monday, February 24th were issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 0.33%. The ex-dividend date was Monday, February 24th. Chemed’s dividend payout ratio (DPR) is 10.05%.

Insider Buying and Selling

In related news, CEO Kevin J. Mcnamara sold 1,000 shares of Chemed stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $615.33, for a total transaction of $615,330.00. Following the sale, the chief executive officer now directly owns 101,679 shares in the company, valued at $62,566,139.07. This trade represents a 0.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.32% of the stock is currently owned by corporate insiders.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.